The application indicates the intellectual energy and resources at St. Jude Children's Research Hospital that will be committed to the Pediatric Brain Tumor Clinical Trials Consortium (PBTCTC). The institutional Neurobiology and Brain Tumor Program represents a talented group of experienced clinical and laboratory investigators (including 22 MD's, PhD's, and PharmD's) with particular expertise in pediatric neuro-oncology, radiation oncology, neurosurgery, molecular pharmacology, pharmacokinetics, neuroimaging, neuropsychology, and biostatistics. The Program accrues an average of 75 newly diagnosed children with brain tumors annually, and is just now positioned to increase accession to phase I and II studies for children with previously treated disease. Amongst the 258 children entered on institutional brain tumor protocols since 1990, significant contributions have been made in medulloblastomas, infant brain tumors, low grade gliomas, and malignant gliomas. During the interval, 154 children have been entered on POG studies, many of which reflect administrative and scientific leadership from St. Jude. Recent protocols highlight collaborations with 2-4 additional institutions to study novel chemotherapeutic and radiotherapeutic interventions, largely derived from laboratory investigation at St. Jude, in medulloblastoma, infant brain tumors, and low grade gliomas/ependymomas. The linear development of protocols (based upon preclinical in vitro and xenograft models, detailed pharmacokinetic studies, and ongoing development of improved means of evaluating tumor response and toxicities) indicates the integration of scientific research and clinical trial design and management that offers considerable expertise as the Program fully commits its resources to the PBTCTC. The development of correlative laboratory studies, including genetic analyses and explorations using the new Patched medulloblastoma model, and translational research evaluating alterations in the Atm gene as potential targets to alter radiation sensitivity, offer enormous potential for the identification of novel therapeutic interventions. The institutional contributions to the PBTCTC combine laboratory and clinical science with a sizable patient base that will be dedicated to consortium trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA081445-01
Application #
2840916
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J2))
Program Officer
Wu, Roy S
Project Start
1999-04-01
Project End
2004-03-31
Budget Start
1999-04-01
Budget End
2000-03-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Reddick, Wilburn E; Taghipour, Delaram J; Glass, John O et al. (2014) Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers. Pediatr Blood Cancer 61:1074-9
Moyer, Katherine H; Willard, Victoria W; Gross, Alan M et al. (2012) The impact of attention on social functioning in survivors of pediatric acute lymphoblastic leukemia and brain tumors. Pediatr Blood Cancer 59:1290-5
Netson, Kelli L; Conklin, Heather M; Ashford, Jason M et al. (2011) Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer. J Pediatr Psychol 36:438-50
Palmer, Shawna L; Reddick, Wilburn E; Glass, John O et al. (2010) Regional white matter anisotropy and reading ability in patients treated for pediatric embryonal tumors. Brain Imaging Behav 4:132-40
Conklin, Heather M; Helton, Susan; Ashford, Jason et al. (2010) Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial. J Pediatr Psychol 35:144-55
Conklin, Heather M; Reddick, Wilburn E; Ashford, Jason et al. (2010) Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors. J Clin Oncol 28:4465-72
Jasper, Bruce W; Conklin, Heather M; Lawford, Joanne et al. (2009) Growth effects of methylphenidate among childhood cancer survivors: a 12-month case-matched open-label study. Pediatr Blood Cancer 52:39-43
Conklin, Heather M; Lawford, Joanne; Jasper, Bruce W et al. (2009) Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. Pediatrics 124:226-33
Conklin, Heather M; Khan, Raja B; Reddick, Wilburn E et al. (2007) Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. J Pediatr Psychol 32:1127-39
Helton, Susan C; Corwyn, Robert F; Bonner, Melanie J et al. (2006) Factor analysis and validity of the Conners Parent and Teacher Rating Scales in childhood cancer survivors. J Pediatr Psychol 31:200-8

Showing the most recent 10 out of 18 publications